The abstract is read at the publisher; the summary is JClub's.
Bone marrow immune age acceleration predicts shorter overall survival in multiple myeloma patients diagnosed before age 70, with HR = 2.24 (p = 0.003) independent of chronological age and clinical fitness.
- Why it matters: Chronological age does not fully explain prognostic differences in multiple myeloma, and existing immune aging clocks based on peripheral blood may miss aging signals in the bone marrow immune microenvironment.
- What they did: The study built bone marrow immune aging clocks for ten immune and progenitor cell types using single-cell RNA-seq from 1,260 healthy peripheral blood and bone marrow samples, then applied them to CoMMpass bone marrow profiles from 337 newly diagnosed patients.
- The result: Accelerated immune aging was linked to shorter overall survival and was driven most by CD4+ memory T cell aging; it also associated with terminal effector differentiation and specific TNF-/NF-{kappa}B and IFN-{gamma} signaling, while monocyte immune age acceleration at first progression predicted shorter subsequent survival (HR = 3.06, p = 0.005).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.